A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
Latest Information Update: 17 May 2025
At a glance
- Drugs AZD 4604 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms AJAX
- Sponsors AstraZeneca
Most Recent Events
- 11 Mar 2025 Planned End Date changed from 30 Sep 2025 to 25 Dec 2025.
- 11 Mar 2025 Planned primary completion date changed from 30 Sep 2025 to 25 Dec 2025.
- 31 Jan 2024 Status changed from not yet recruiting to recruiting.